News Headline Summary

Eisai (4523 JT) says breast cancer drug Halaven fails to show advantage over Roche's Xeloda in cases where disease had spread to other parts of body

09 Dec 2012 - 23:29 - Equities - Source: Newswires

Subscribe Now to RANsquawk

Click here for a 1 week free trial

RANsquawk provides audio news and commentary for over 15,000 professional traders and brokers worldwide. Services include: